Enrique M. Ocio, David Vilanova, Peter Atadja, Patricia Maiso, Edvan Crusoe, Diego Fernández-Lázaro, Mercedes Garayoa, Laura San-Segundo, Teresa Hernández-Iglesias, Enrique de Álava, Wenlin Shao, Yung-Mae Yao, Atanasio Pandiella, Jesús F. San-Miguel. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. haematol [Internet]. 2010May4 [cited 2024Dec.23];95(5):794-03. Available from: https://haematologica.org/article/view/5592